Pacira BioSciences
Pacira BioSciences develops non-opioid therapies for postsurgical, chronic, and musculoskeletal pain, with more than 18 million patients treated to date. The company's commercial portfolio includes EXPAREL and ZILRETTA, and its pipeline features PCRX-201, a gene therapy candidate for knee osteoarthritis. Pacira also works to expand patient access to non-opioid options through education, advocacy, and coverage initiatives.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Opioid overprescription and reliance on opioids for pain management, particularly after surgery, contribute to addiction and public health crises. Patients and providers lack sufficient non-opioid alternatives that are effective, accessible, and covered by insurance, leaving many to face significant pain with inadequate or risky treatment options.
Solution
Pacira BioSciences provides a portfolio of non-opioid therapies designed to manage pain across postsurgical, chronic, and musculoskeletal settings. The company's commercial products include EXPAREL, a long-acting local anesthetic, and ZILRETTA, an extended-release treatment for osteoarthritis knee pain. Pacira also advances an investigational pipeline, including PCRX-201, a gene therapy candidate for knee osteoarthritis, and PCRX-2002, aimed at transforming osteoarthritis treatment. The company supports patients and providers through education, shared decision-making tools, and advocacy efforts to expand access to non-opioid pain management options.
Target Audience
Primary customers are healthcare providers, including surgeons and pain specialists, as well as patients undergoing surgery or living with chronic or musculoskeletal pain. The company also engages with policymakers, payers, and patient advocacy groups to expand coverage and adoption of non-opioid therapies.
Features
- EXPAREL: a non-opioid, long-acting local anesthetic for postsurgical pain management
- ZILRETTA: an extended-release, non-opioid treatment for osteoarthritis knee pain
- PCRX-201: an investigational gene therapy candidate for knee osteoarthritis designed to help patients return to normal function
- PCRX-2002: an additional pipeline candidate for pain management
- Patient education resources and tools to support shared decision-making between patients and providers
- Advocacy initiatives, including seed funding for Voices for Non-Opioid Choices, to drive reimbursement policy reform and expand access to non-opioid options